Total small vessel disease burden and functional outcome in patients with ischemic stroke

Wi-Sun Ryu1,2*, Sang-Wuk Jeong1,2, Dong-Eog Kim1,2

1 Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea, 2 Korean Brain MRI Data Center, Goyang, Republic of Korea

* wisunryu@gmail.com

Abstract

Background

Cerebral small vessel disease (SVD) is comprised of lacunes, cerebral microbleeds (CMBs), white matter hyperintensities (WMHs), and enlarged perivascular space (EPVS). We investigated the cumulative effect of SVD on 3-month functional outcome following ischemic stroke using the total SVD score.

Methods

The total SVD score of 477 acute ischemic stroke patients with adequate brain MRI was analyzed. We used multivariable ordinal logistic regression analysis to investigate the independent impact of total SVD score on ordinal modified Rankin Scale (mRS) score at 3-month after ischemic stroke.

Results

Mean age was 66±14 years, and 61% were men. The distribution of the total SVD score from 0 to 4 was 27%, 24%, 26%, 16%, and 7%, respectively. The proportion of mRS scores 2 or greater was 16% and 47% in total SVD score 0 and 4, respectively. Multivariable ordinal logistic regression analysis results showed that compared with the total SVD score of 0, total SVD scores of 2, 3, and 4 were independently associated with higher mRS scores with adjusted odds ratios (95% confidence intervals) of 1.68 (1.02–2.76), 2.24 (1.25–4.00), and 2.00 (1.02–4.29). Lacunes, CMBs, WMHs but not EPVS were associated with mRS scores at 3 months. However, the impact of each SVD marker on stroke outcome was smaller than that of the total SVD score.

Conclusion

We found an independent association between total SVD scores and functional outcome at 3 months following ischemic stroke. The total SVD score may be useful for stratification of patients who are at a high-risk of unfavorable outcomes.
Introduction
Cerebral small vessel disease (SVD) is frequently observed in MRIs of ischemic stroke patients [1]. White matter hyperintensities (WMH), lacunes, cerebral microbleeds (CBMs), and enlarged perivascular space (EPVS) are neuroimaging markers of SVD [2]. Accumulating evidence has suggested that SVD is associated with incident stroke, recurrent stroke, and vascular cognitive impairment [1, 3]. In addition, SVD portends unfavorable functional outcome after ischemic stroke [4–6]. This has been shown in a recent large-sample sized study, patients with the highest quintile of WMHs had a nearly two-fold increased risk of higher modified Rankin Scale (mRS) score at 3-months than those in the lowest quintile [6].

In general, prior studies have reported on the clinical implication of individual SVD markers after ischemic stroke [6–9]. However, in clinical practice, SVD markers are often simultaneously present in a single patient. Hence, the cumulative effect of SVD markers has been recently highlighted, and a simple SVD score has been proposed and validated [10, 11]. A few studies have made observations on the impact of SVD score on functional outcome after ischemic stroke [12–14]. However, these studies are limited because they used incomplete SVD score (a combination of WMH and lacunes, or exclusion of CMBs). In the present study, we investigated the effect of the cumulative SVD burden on the 3-month functional outcome after ischemic stroke using the total SVD score.

Methods
Study population
We performed post hoc analysis on prospectively-collected data from a single-center stroke registry. From February 2012 to September 2013, we included a total of 687 patients who visited our center within 7 days of stroke onset and were confirmed to have had ischemic stroke based on brain MRI. The institutional review board of Dongguk University Ilsan Hospital approved the study protocol, and all participants gave written informed consent. The study protocol was conducted in accordance with the Declaration of Helsinki.

Clinical data and outcome measurement
National Institutes of Health Stroke Scale (NIHSS) score at admission, pre-stroke mRS score, and mRS score at three months after stroke were collected prospectively. Under a standardized protocol [6, 15], we collected demographic data, prior medication history, laboratory data, past medical history including risk factors for stroke such as hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, atrial fibrillation, and smoking history. Stroke subtypes were determined by the consensus of experienced neurologists, using a validated MRI-based algorithm [16].

MRI scoring
We obtained MRI with a 1.5 T or 3.0 T MR scanner, and the images included standard axial T2–weighted fast spin echo-images, axial fluid-attenuated inversion recovery (FLAIR) images, and T2-weighted gradient echo-images. A stroke neurologist (W. R.) blinded to the clinical data provided ratings for all of the obtained imaging. In accordance with the STRIVE guidelines [2], we defined lacunes as rounded or ovoid lesions, 3–15 mm in diameter, located in the basal ganglia, internal capsule, centrum semiovale, or brainstem, of CSF signal intensity on T2 and FLAIR, generally with a hyperintense rim on FLAIR and no increased signal on diffusion-weighted image (DWI). We quantified WMH volume, as previously described [17, 18]. In brief, brain template images (1 × 1 × 1 mm³ voxel) were chosen from the Montreal...
Neurological Institute (MNI) template within the range of -63.5 to 74.5 mm in the Z-axis of the MNI coordinate space. After normalization of images, each patient’s high signal intensity lesions on FLAIR were semi-automatically segmented and registered onto the brain templates under careful supervision by a vascular neurologist (W. R.). When chronic lesions on FLAIR and acute lesions on DWI overlapped, the extent and distribution of FLAIR WMH contralateral to the location of acute infarct served as a reference to determine what volumes to include and exclude, by assuming the symmetric distribution of WMHs across the midline. We calculated the WMH volume on FLAIR as a percentage of total brain volume by dividing the number of voxels in the lesions over the total number of brain voxels, with corrections applied to account for the differences in scan slice thicknesses by adjusting the denominators. We defined EPVS as round, oval, or linear-shaped lesions with a smooth margin, absence of mass effect, and with a signal intensity equal to CSF on T2-weighted images and hypointense on FLAIR images without a hyperintense rim to distinguish them from old lacune. We counted EPVS at the level of the centrum semiovale and basal ganglia with a validated four-point visual rating scale (0 = none; 1 = 1–10; 2 = 11–20; 3 = 21–40; and 4 = >40) [19]. We counted enlarged perivascular spaces on the slide with the highest number in one hemisphere. We defined CMBs as rounded hypointense lesions on T2-weighted gradient echo-images with a diameter ≤ 10 mm. To calculate the total SVD score, we used a 5-point ordinal score developed by Klarenbeek et al. [11]. A point was awarded if one or more lacunes were present, or WMH was found to be above the median of WMH volume, or one or more CMBs were present, or EPVS was found to be of moderate to severe degree (scored 2–4). Hence, the total SVD score ranged from a minimum score of 0 to a maximum of 4.

**Statistical analysis**

Data are presented as mean [standard deviation (SD)], median [interquartile range (IQR)], and number (percentage), as appropriate. We compared baseline characteristics between total SVD scores using the chi-square test and ANOVA. For the skewed continuous variable, we used the Kruskal-Wallis test. To examine the distribution of the mRS score by total SVD score, we used the chi-square test. To investigate whether there is an independent association between total SVD score and functional outcome after ischemic stroke, we used multivariable ordinal logistic regression analysis with mRS scores as an ordinal outcome variable. Predefined covariates potentially associated with functional outcome after ischemic stroke, including age, sex, pre-stroke mRS score, initial NIHSS scores, previous history of stroke, hypertension, diabetes, smoking, coronary artery disease, stroke subtypes, and revascularization, were entered into the multivariable model. Data were analyzed using STATA 16.0 software (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC), and p < 0.05 were considered statistically significant.

**Results**

Among 687 patients who were screened, we excluded those with the following to calculate the total SVD score; patients with incomplete MRI sequences (n = 135), poor MRI quality (n = 32), and lost to follow-up (n = 43), leaving 477 patients for the analyses. The mean age was 66.3 (standard deviation 14.1), 38% were women (n = 183), the median NIHSS 3 (interquartile range 1–5), and the median WMH volume was 0.85% of total brain volume (interquartile range 0.39–1.80). Prevalences of lacunes, CMBs, and EPVS were 53%, 26%, and 56%, respectively. The distribution of the total SVD score from 0 to 4 was 27%, 24%, 26%, 16%, and 7%, respectively. The patients with higher total SVD scores were older and had a history of hypertension compared to those with lower total SVD scores (Table 1). Previous stroke history and hyperlipidemia were more prevalent in patients with higher total SVD scores than those with...
lower total SVD scores. In addition, NIHSS scores increased along with total SVD scores. Each SVD marker was associated with other markers of SVD (Fig 1). Compared with patients without lacunes, those with lacunes had more prevalent CBMs, above median of WMH, and EPVS (all $P < 0.001$). This association was observed in CMBs, WMH, and EPVS.

Fig 2 demonstrated the distribution of mRS score at 3-month after ischemic stroke stratified by total SVD scores. As the total SVD score increased, more patients had high mRS scores ($P < 0.001$ by chi-square test). In multivariable ordinal logistic regression analyses (Table 2), lacune (adjusted odds ratio 1.69, 95% confidence interval 1.16–2.47, $P = 0.006$), CMBs (adjusted odds ratio 1.94, 95% confidence interval 1.31–2.88, $P = 0.001$), and WMH (adjusted odds ratio 1.86, 95% confidence interval 1.24–2.80, $P = 0.003$) were independently associated with 3-month mRS scores. However, EPVS was not associated with 3-month mRS scores. When the total SVD score was entered as a dependent variable, 2, 3, and 4 points of total SVD scores were independently associated with unfavorable outcome compared with 1 point of total SVD score. Adjusted odds ratios (95% confidence interval) for 2, 3, and 4 points of total SVD scores were 1.68 (1.02–2.76), 2.24 (1.25–4.00), and 2.00 (1.02–4.29), respectively.

Discussion
In the present study, we found an independent association between total SVD scores and functional outcome at three months following ischemic stroke. Patients with total SVD scores of 3

| Table 1. Baseline characteristics and total small vessel disease score. |
|--------------------------|--------------------------|--------------------------|--------------------------|
| All patients (N = 477)   | Small vessel disease score (N = 477) | p value |
| Age, years               | 66±14                   | 55±15                    | 65±13                    | 70±13                    | 72±10                    | 76±10                    | 0.01 |
| Sex, men                 | 294 (62%)               | 81 (62%)                 | 75 (66%)                 | 81 (65%)                 | 42 (55%)                 | 15 (47%)                 | 0.19 |
| Pre-stroke mRS 2 or more | 60 (13%)                | 4 (5%)                   | 11 (10%)                 | 19 (15%)                 | 12 (16%)                 | 12 (38%)                 | <0.001 |
| Previous stroke          | 99 (21%)                | 9 (10%)                  | 19 (17%)                 | 32 (26%)                 | 26 (34%)                 | 13 (41%)                 | <0.001 |
| Hypertension             | 359 (75%)               | 77 (59%)                 | 84 (74%)                 | 100 (81%)                | 68 (88%)                 | 30 (94%)                 | <0.001 |
| Diabetes                 | 182 (38%)               | 41 (32%)                 | 43 (38%)                 | 54 (44%)                 | 30 (39%)                 | 14 (44%)                 | 0.36 |
| Hyperlipidemia           | 143 (30%)               | 27 (21%)                 | 36 (32%)                 | 36 (29%)                 | 32 (41%)                 | 12 (38%)                 | 0.024 |
| Smoking, current or quit | 3 years                 | 221 (46%)                | 61 (47%)                 | 58 (51%)                 | 60 (48%)                 | 31 (40%)                 | 11 (34%)                 | 0.39 |
| Coronary artery disease  | 75 (16%)                | 16 (12%)                 | 14 (12%)                 | 23 (19%)                 | 16 (21%)                 | 6 (19%)                  | 0.33 |

The following values of the presented data are shown: mean±standard deviation, number (percentage), or median (inter-quartile range).

* Data are missing for one patient.

†Percentage of total brain volume.

mRS indicates modified Rankin Scale score; IQR, interquartile range; WMH, white matter hyperintensity; CMB, cerebral microbleeds; EPVS, enlarged perivascular space.

https://doi.org/10.1371/journal.pone.0242319.t001.
and 4 had a two-fold increased risk of higher mRS score at three months after ischemic stroke compared with those with a total SVD score of 0. In addition, we found among SVD markers, lacune, CMBs, and WMHs are independently associated with functional outcome. However, EPVS was not associated with functional outcome at 3-month after ischemic stroke.

In line with previous studies [5, 6, 9], we found that lacunes, CMBs, and WMHs are independently associated with unfavorable functional outcome at 3-months. These SVD markers are associated with early neurological deterioration and recurrence of stroke [6, 20]. Moreover, extensive WMH renders the brain to be more vulnerable to ischemic injury and expansion of ischemic stroke [21]. Also, patients with severe WMH or lacunes may be physically inactive
and cognitively impaired, which hampers active rehabilitation and functional regain after ischemic stroke [6].

In the present study, we found no association between EPVS and functional outcome after ischemic stroke. Although several studies have reported on the relation of EPVS with incident stroke, dementia, and recurrence after ischemic stroke [22–24], a recent study showed no association between EPVS and stroke outcome [14]. These data suggest that EPVS may have a different clinical impact on the brain with ischemic stroke from other neuroimaging markers of SVD, although EPVS has similar risk factors with other SVD markers. Indeed, we also found a positive relation between EPVS and other markers of SVD; patients with EPVS had more prevalent lacunes, CMBs, and WMH compared with those without EPVS. However, further studies are needed to delineate the clinical implications of EPVS in patients with ischemic stroke.

Neuroimaging markers of SVD are frequently observed together in patients with ischemic stroke [14]. Hence, it is helpful to quantify the total SVD burden to evaluate the cumulative effect of SVD in patients with ischemic stroke. In the present study, we found the cumulative effect of SVD on functional outcome after ischemic stroke. Compared to the effect of a single SVD marker, the effect of the quantified total SVD score was found to be greater. In the present study, the effects of total SVD scores of 3 and 4 were comparable. This may be a result from the lack of association between EPVS and stroke outcome, and thus a total SVD scores 3 or 4 could be a reasonable point to discriminate the group of a high risk of unfavorable outcome.

Several limitations of our study deserve comment. First, patients with severe stroke and revascularization therapy may have been excluded from the study. As a result, this selection bias may underestimate the degree of association between total SVD burden and function outcomes because SVD is associated with functional outcomes in patients who received thrombectomy [25] and intravenous recombinant tissue plasminogen activator [12]. Second, data from a single center and single ethnicity may have limited generalizability. Third, because the present study included only patients with MRI, our results have limited generalizability to patients who undergo only brain computed tomography (CT). Fourth, a total SVD score did

| Total SVD score | Adjusted odds ratio (95% confidence interval) | p value |
|-----------------|-------------------------------------------|---------|
| 0               | Reference                                 |         |
| 1               | 0.96 (0.58–1.58)                           | 0.87    |
| 2               | 1.73 (1.05–2.83)                           | 0.031   |
| 3               | 2.18 (1.22–3.88)                           | 0.008   |
| 4               | 2.21 (1.04–4.69)                           | 0.038   |

p for trend 0.008

| Presence of lacunes | 1.63 (1.13–2.38) | 0.009 |
|---------------------|------------------|-------|
| Presence of CMBs    | 1.88 (1.28–2.76) | 0.001 |
| Presence of EPVS    | 1.19 (0.84–1.70) | 0.32  |
| Above median of WMH volume* | 1.87 (1.25–2.81) | 0.002 |

Adjusted for age, sex, initial National Institute Health stroke scale (NIHSS) scores, pre-stroke mRS score, previous history of stroke, hypertension, diabetes, smoking, coronary artery disease, stroke subtypes, and revascularization. Multivariable ordinal logistic regression analysis was performed for each dependent variable.

* Median = 0.85% of total brain volume

SVD indicates small vessel disease; CMB, cerebral microbleed; EPVS, enlarged perivascular space; WMH, white matter hyperintensity.

https://doi.org/10.1371/journal.pone.0242319.t002
not contain information on the severity of each SVD phenotype. Irrespective of the number of lacunes, the presence of lacune awards one point. Future SVD scoring system that includes information on the severity of each marker of SVD may be useful.

In conclusion, we found an independent association between total SVD score and functional outcome at 3-month after ischemic stroke. Compared with a single marker of SVD, the total SVD score may provide more comprehensive information and improve personalized care for ischemic stroke patients.

Acknowledgments
We thank Dr. Jung E Park for assistance with English language editing.

Author Contributions
Conceptualization: Wi-Sun Ryu.
Data curation: Wi-Sun Ryu, Sang-Wuk Jeong, Dong-Eog Kim.
Formal analysis: Wi-Sun Ryu, Dong-Eog Kim.
Funding acquisition: Wi-Sun Ryu.
Investigation: Wi-Sun Ryu.
Methodology: Wi-Sun Ryu, Sang-Wuk Jeong.
Resources: Sang-Wuk Jeong, Dong-Eog Kim.
Supervision: Wi-Sun Ryu, Dong-Eog Kim.
Writing – original draft: Wi-Sun Ryu.
Writing – review & editing: Sang-Wuk Jeong, Dong-Eog Kim.

References
1. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013; 12(5):483–97. https://doi.org/10.1016/S1474-4422(13)70060-7 PMID: 23602162
2. Wardlaw JM, Smith EE, Bessesen GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12(8):822–38. https://doi.org/10.1016/S1474-4422(13)70124-8 PMID: 23867200
3. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9(7):689–701. https://doi.org/10.1016/S1474-4422(10)70104-6 PMID: 20610345
4. Sagnier S, Catheline G, Diharreguy B, Linck PA, Coupe P, Munsch F, et al. Normal-Appearance White Matter Integrity Is a Predictor of Outcome After Ischemic Stroke. Stroke 2020; 51(2):449–56. https://doi.org/10.1161/STROKEAHA.119.026886 PMID: 31906830
5. Chardimou A, Pasi M, Fiorelli M, Shams S, von Kummer R, Pantoni L, et al. Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1). Stroke 2016; 47(9):2364–72. https://doi.org/10.1161/STROKEAHA.116.014096 PMID: 27491738
6. Ryu WS, Woo SH, Schellingerhout D, Jang MU, Park KJ, Hong KS, et al. Stroke outcomes are worse with larger leukoaraiosis volumes. Brain 2017; 140(1):158–70. https://doi.org/10.1093/brain/aww259 PMID: 28008000
7. Inzitari D, Eliasziw M, Sharpe BL, Fox AJ, Barnet HJ. Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. North American Symptomatic Carotid Endarterectomy Trial Group. Neurology 2000; 54(3):660–6. https://doi.org/10.1212/wnl.54.3.660 PMID: 10680600
8. Choi KH, Kim JH, Kang KW, Kim JT, Choi SM, Lee SH, et al. Impact of Microbleeds on Outcome Following Recanalization in Patients With Acute Ischemic Stroke. Stroke 2018;STROKEAHA118023084. https://doi.org/10.1161/STROKEAHA.118.023084 PMID: 30590721
9. Charidimou A, Turc G, Oppenheim C, Yan S, Schelitz JF, Erdur H, et al. Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis. Stroke 2017; 48(8):2084–90. https://doi.org/10.1161/STROKEAHA.116.012992 PMID: 28720659

10. Lau KK, Li L, Schulz U, Simoni M, Chan KH, Ho SL, et al. Total small vessel disease score and risk of recurrent stroke: Validation in 2 large cohorts. Neurology 2017; 88(24):2260–7. https://doi.org/10.1212/WNL.0000000000004042 PMID: 28515266

11. Klarenbeek P, van Oostenbrugge RJ, Rouhl RP, Knottnerus IL, Staals J. Ambulatory blood pressure in patients with lacunar stroke: association with total MRI burden of cerebral small vessel disease. Stroke 2013; 44(11):2995–9. https://doi.org/10.1161/STROKEAHA.113.002545 PMID: 23982717

12. Arba F, Inzitari D, Ali M, Warach SJ, Luby M, Lees KR, et al. Small vessel disease and clinical outcomes after IV rt-PA treatment. Acta Neurol Scand 2017; 136(1):72–7.

13. Arba F, Palumbo V, Boulanger JM, Pracucci G, Inzitari D, Buchan AM, et al. Leukoaraiosis and lacunes are associated with poor clinical outcomes in ischemic stroke patients treated with intravenous thrombolysis. Int J Stroke 2016; 11(1):62–7. https://doi.org/10.1177/1747493015607517 PMID: 26763021

14. Huo YC, Li Q, Zhang WY, Zou N, Li R, Huang SY, et al. Total Small Vessel Disease Burden Predicts Functional Outcome in Patients With Acute Ischemic Stroke. Front Neurol 2019; 10:808. https://doi.org/10.3389/fneur.2019.00808 PMID: 31447754

15. Ryu WS, Schellinghout D, Hong KS, Jeong SW, Jang MU, Park MS, et al. White matter hyperintensity load on stroke recurrence and mortality at 1 year after ischemic stroke. Neurology 2019; 93(6):e578–e89. https://doi.org/10.1212/WNL.0000000000007896 PMID: 31308151

16. Ko Y, Lee S, Chung JW, Han MK, Park JM, Kang K, et al. MRI-based Algorithm for Acute Ischemic Stroke Subtype Classification. J Stroke 2014; 16(3):161–72.

17. Ryu WS, Woo SH, Schellinghout D, Chung MK, Kim CK, Jang MU, et al. Grading and interpretation of white matter hyperintensities using statistical maps. Stroke 2014; 45(12):3567–75. https://doi.org/10.1016/j.stroke.2014.02.023 PMID: 25388424

18. Kim DE, Park JH, Schellinghout D, Ryu WS, Lee SK, Jang MU, et al. Mapping the Supratentorial Cerebral Arterial Territories Using 1160 Large Artery Infarcts. JAMA Neurology 2019; 76(1):72–80.

19. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis 2015; 39(3–4):224–31. https://doi.org/10.1159/000375153 PMID: 25823458

20. Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ. Neuroimaging markers for early neurologic deterioration in single small subcortical infarction. Stroke 2015; 46(3):687–91. https://doi.org/10.1161/STROKEAHA.114.006662 PMID: 25677600

21. Ay H, Arsava EM, Rosand J, Furie KL, Singhal AB, Schaefer PW, et al. Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke 2008; 39(5):1409–13. https://doi.org/10.1161/STROKEAHA.107.501932 PMID: 18340093

22. Hilai S, Tan CS, Adams HH, Habes M, Mok V, Venkatasubramanian N, et al. Enlarged perivascular spaces and cognition: A meta-analysis of 5 population-based studies. Neurology 2018; 91(9):e832–e42. https://doi.org/10.1212/WNL.0000000000006079 PMID: 30068634

23. Arba F, Quinn TJ, Hankey GJ, Lees KR, Wardlaw JM, Ali M, et al. Enlarged perivascular spaces and cognitive impairment after stroke and transient ischemic attack. Int J Stroke 2018; 13(1):47–56. https://doi.org/10.1177/1747493016666091 PMID: 27543501

24. Brown R, Benveniste H, Black SE, Charpak S, Dicghans M, Joutel A, et al. Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovasc Res 2018; 114(11):1462–73. https://doi.org/10.1093/cvr/cvy113 PMID: 29726891

25. Arba F, Testa GD, Limbucci N, Nappini S, Renieri L, Pracucci G, et al. Small vessel disease and clinical outcomes after endovascular treatment in acute ischemic stroke. Neurol Sci 2019; 40(6):1227–35. https://doi.org/10.1007/s10072-019-03824-4 PMID: 30874998